Immunotherapy for Infectious Diseases

194 Kalams
66. Altfeld M, Rosenberg ES, Shankarappa R, et al. Cellular imune responses and viral diversity
in individuals treated during acute and early HIV-1 infection. J Exp Med 2001;
193:169.
67. Pantaleo G, Graziosi C, Demarest JF, et al. Role of lymphoid organs in the pathogenesis
of human immunodeficiency virus (HIV) infection [Review]. Immunol Rev 1994; 40:105.
68. Race EM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymphadenitis following
initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease.
Lancet 1998; 351:252.
69. Karavellas MP, Lowder CY, Macdonald C, Avila CP, Freeman WR. Immune recovery vitritis
associated with inactive cytomegalovirus retinitis: a new syndrome. Arch Ophthalmol
1998; 116:169.
70. Karavellas MP, Plummer DJ, Macdonald JC, et al. Incidence of immune recovery vitritis
in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral
therapy. J Infect Dis 1999; 179:697.
71. Reed JB, Schwab IR, Gordon J, Morse LS. Regression of cytomegalovirus retinitis associated
with protease-inhibitor treatment in patients with AIDS. Am J Ophthalmol 1997;
124:199.
72. John M, Flexman J, French MA. Hepatitis C virus-associated hepatitis following treatment
of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?
AIDS 1998; 12:2289.
73. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover
of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123.
74. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo:
virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271:1582.
75. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments
during combination therapy. Nature 1997; 387:188.
76. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on
CD4� T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112.
77. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of
human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease
inhibitor, ritonavir. J Infect Dis 1996; 173:321.
78. Angel JB, Kumar A, Parato K, et al. Improvement in cell-mediated immune function during
potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir.
J Infect Dis 1998; 177:898.
79. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery
in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy
in advanced HIV-1 disease. Lancet 1998; 351:1682.
80. Pitcher CJ, Quittner C, Peterson DM, et al. HIV-1-specific CD4� T cells are detectable
in most individuals with active HIV-1 infection, but decline with prolonged viral suppression.
Nat Med 1999; 5:518.
81. Ogg GS, Jin X, Bonhoeffer S, et al. Decay kinetics of human immunodeficiency virusspecific
effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol
1999; 73:797.
82. Markowitz M, Vesanen M, Tenner-Racz K, et al. The effect of commencing combination
antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral
replication and antiviral immune responses. J Infect Dis 1999; 179:527.
83. Kalams SA, Goulder PJ, Shea AK, et al. Levels of human immunodeficiency virus type
1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression
of viremia with highly active antiretroviral therapy. J Virol 1999; 73:6721.
84. Connors M, Kovacs JA, Krevat S, et al. HIV infection induces changes in CD4� T-cell
phenotype and depletions within the CD4� T-cell repertoire that are not immediately
restored by antiviral or immune-based therapies. Nat Med 1997; 3:533.